Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2'deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice.
Systemic or topical treatment with E-5-(2-bromovinyl)2'-deoxyuridine (BVDU) showed significant efficacy against orofacial infection with herpes simplex virus type 1 (HSV-1) in hairless mice. The chemotherapeutic response to BVDU was dose-dependent and clearly evident even when the treatment was initiated during the clinical manifestation of HSV-1 infection at 72 hr after inoculation. Early initiation of therapy with BVDU at 3 or 24 hr after inoculation significantly prevented the establishment of latent HSV infection in the trigeminal ganglia of mice, but systemic treatment with BVDU did not influence already established latent HSV-1. The chemotherapeutic efficacy of BVDU was comparable to that of acyclovir in the present animal model.
D000212:Acyclovir; D000287:Administration, Topical; D000818:Animals; D001973:Bromodeoxyuridine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005145:Face; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006560:Herpes Labialis / Q000188:drug therapy*; D006561:Herpes Simplex / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013997:Time Factors; D012668:Trigeminal Ganglion / Q000382:microbiology
C020235:brivudine; D006147:Guanine; D001973:Bromodeoxyuridine; D000212:Acyclovir